A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 08 Jul 2019
At a glance
- Drugs Elotuzumab (Primary) ; Bortezomib; Bortezomib; Dexamethasone; Dexamethasone; Lenalidomide
- Indications Multiple myeloma; Plasma cell leukaemia
- Focus Therapeutic Use
- 03 Jul 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Dec 2019.
- 30 May 2019 Planned primary completion date changed from 1 May 2019 to 1 Oct 2019.
- 10 Oct 2018 Planned primary completion date changed from 1 Sep 2018 to 1 May 2019.